Type 2 diabetes drug may lower heart attack, stroke risk by 23%

Evan Walker
Evan Walker TheMediTary.Com |
An older adult man out in a sports field, looking to the sideShare on Pinterest
A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, too. Richard Drury/Getty Images
  • According to estimates, one in three people who have type 2 diabetes also have chronic kidney disease.
  • Both chronic conditions are associated with an increased risk of stroke and heart attack.
  • A new study has found a medication already used to treat people who have type 2 diabetes and/or chronic kidney disease with added heart disease risks also helps lower their stroke and heart attack risk.

Researchers estimate that as many as 840 million people globally live with chronic kidney disease — a disease that steadily damages the kidneys, leading to function loss.

Another estimated 828 million people around the world have diabetes, which is when their body does not use or make insulin properly. Up to 95% of people with diabetes have type 2 diabetes.

While these are two separate chronic conditions, they are linked as about one in every three adults with type 2 diabetes also has chronic kidney disease.

Additionally, both conditions are associated with an increased risk for cardiovascular complications such as stroke and heart attack.

Now, a new study recently published in the journal The Lancet Diabetes & Endocrinologyhas found that a U.S. FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease with added heart disease risks also helps lower their stroke and heart attack risk.

When asked how sotagliflozin might help lower heart attack and stroke risk, Bhatt said it may be because the drug also blocks the SGLT1 (sodium-glucose cotransporter 1) receptor as well.

“This receptor is found in the kidneys, gut, heart, and brain,” he explained. “These additional sites of action may explain why sotagliflozin reduces the risk of both heart attack and stroke, and those other drugs do not.”

“In patients with diabetes, kidney disease, and additional cardiovascular risk factors, combined inhibition of the SGLT2 and SGLT1 receptors by sotagliflozin reduces the risk of heart failure, kidney disease progression, heart attacks, and strokes. This multi-pronged approach could lead to a substantial reduction in cardiovascular risk in eligible patients who are treated with this medication.”
— Deepak L. Bhatt, MD, MPH, MBA

When asked about the next steps for this research, Bhatt said that sotagliflozin should be studied in other populations at high risk for heart attack and stroke.

“Those would need to be large, long-term trials, so we would need to find someone to fund such research,” he continued. “In the meantime, smaller basic science experiments are ongoing to examine the biological actions of blocking SGLT1 receptors that may explain sotagliflozin’s unique ability (among the SGLT inhibitor class of drugs) to reduce heart attack and stroke risk.”

“SGLT2 inhibitors have become an important part of our treatment of patients with heart failure,” Broukhim said. “If sotagliflozin has the added benefit of reduction in myocardial infarction and stroke, we may wish to use this agent more to treat high risk patients.”

“People with type 2 diabetes or kidney disease have significantly elevated risks for heart attack and stroke despite our available treatments. If we have additional agents that can reduce risks of heart and stroke, that will help us improve the lives of these high-risk patients.”
— Michael Broukhim, MD

“I would like to see more data differentiating the actions of a SGLT2 inhibitor and an agent that inhibits both SGLT1 and SGLT2, including some comparative effectiveness research to see if there is a true difference between the various agents that we are utilizing, and if certain patient populations will benefit more from one particular agent over the other,” Broukhim added.

TAGGED: , , , ,
Share this Article